Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2024-05662 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| 20350 | Other Identifier | Fred Hutch/University of Washington Cancer Consortium |
Not provided
Not provided
Not provided
Study closed before opening to accrual; Insufficient staff
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial evaluates a palliative care consultation for improving communication between providers and patients considering surgery for a pancreatic neoplasm. Pancreatic operations have known complications that can affect quality of life. Palliative care has been shown to improve patient reported quality of life and functional outcomes. Receiving a palliative care consultation may improve communication and decision making for patients considering surgery for a pancreatic neoplasm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline.
ARM II: Patients attend a palliative care visit over 60 minutes to discuss their illness, quality of life, fears and concerns and communication preferences within 7 days of baseline. Patients also undergo evaluation by a tumor board within 14 days of baseline.
After completion of study intervention, patients are followed up 7 days after the tumor board visit and 90 days after initiation of treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm I (Usual care) | Active Comparator | Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline. |
|
| Arm II (Palliative care visit) | Experimental | Patients attend a palliative care visit over 60 minutes to discuss their illness, quality of life, fears and concerns and communication preferences within 7 days of baseline. Patients also undergo evaluation by a tumor board within 14 days of baseline. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Best Practice | Other | Receive usual care |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of recruited patients that consent (acceptability) | Acceptability will be defined as ≥ 60% of recruited patients consented. | At time of consent |
| Percentage of patients randomized to the interventional arm who complete the palliative care consult prior to tumor board (feasibility) | Feasibility will be defined as ≥ 60% of patients randomized to interventional arm who complete palliative care consult prior to pancreatic cancer specialty clinic tumor board. | At time of multidisciplinary tumor board discussion (No more than 14 days after baseline) |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of participants who complete the decisional conflict scale | At completion of 7 day follow-up timepoint | |
| Percentage of participants who complete study measures within the first 90 days | At completion of 90 day follow-up timepoint |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Elizabeth Loggers | Fred Hutch/University of Washington Cancer Consortium | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Palliative Care Consultation | Procedure | Attend a palliative care visit |
|
| Survey Administration | Other | Ancillary studies |
|
| Tumor Board Review | Other | Undergo evaluation by tumor board |
|
|
| Percentage of participants randomized to usual care who go on to receive palliative care within the active study period | At 90 day follow-up timepoint |
| ID | Term |
|---|---|
| D010190 | Pancreatic Neoplasms |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D004066 | Digestive System Diseases |
| D010182 | Pancreatic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D017410 | Practice Guidelines as Topic |
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D017408 | Guidelines as Topic |
| D011785 | Quality Assurance, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
| D019984 | Quality Indicators, Health Care |
Not provided
Not provided